US › Healthcare

Cognition Therapeutics Inc (CGTX)

US · Healthcare · Biotechnology

$0.99+10.61%

Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue

Net profit

$-4.6M

Profit YoY

+46.1%

EPS

$-0.05

EPS estimate

$-0.07

EPS came in at -0.05 against a street estimate of -0.07 — a beat of 28.6%.

Key statistics

Market cap

$80.6M

Forward P/E

0.0

P/B

2.68

Book value

$0.34

EPS (TTM)

$-0.23

52-week high

$3.83

52-week low

$0.55

50-day MA

$1.15

200-day MA

$1.28

Beta

1.75

Analyst view

Analysts rate Cognition Therapeutics Inc a strong buy (4 buy, 0 hold, 0 sell out of 4) with an average price target of $3.50.

Shareholding

Insiders

1.37%

Institutions

25.02%

Largest institutional holders

Fund	Stake
BIOS CAPITAL MANAGEMENT, LP	6.70%
Davenport & Company LLC	4.76%
Vanguard Group Inc	3.71%
Vanguard Capital Management, LLC	3.35%
Renaissance Technologies Corp	1.25%
Chescapmanager LLC	1.11%
BlackRock Inc	1.08%
Geode Capital Management, LLC	1.03%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Cognition Therapeutics Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Novo Nordisk A/S Amgen Inc Abbott Laboratories Gilead Sciences Inc

Data updated 2026-08-05.